Compare GPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | CHRS |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.4M | 186.0M |
| IPO Year | 2014 | 2014 |
| Metric | GPRO | CHRS |
|---|---|---|
| Price | $1.61 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.02 |
| AVG Volume (30 Days) | ★ 3.2M | 959.3K |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | ★ $650,751,000.00 | $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.41 | $67.29 |
| P/E Ratio | ★ N/A | $2.58 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $0.40 | $0.71 |
| 52 Week High | $3.05 | $1.89 |
| Indicator | GPRO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 53.23 |
| Support Level | $1.50 | $1.31 |
| Resistance Level | $1.92 | $1.41 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 25.08 | 77.34 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.